BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $136.4185.

Several brokerages have recently weighed in on BNTX. HC Wainwright increased their target price on shares of BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Jefferies Financial Group reissued a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a research report on Wednesday. Morgan Stanley reissued an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. JPMorgan Chase & Co. cut their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. Finally, Bank of America decreased their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd.

BioNTech Price Performance

NASDAQ:BNTX opened at $96.25 on Friday. The firm has a market capitalization of $21.67 billion, a price-to-earnings ratio of -36.60 and a beta of 1.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The business has a 50 day simple moving average of $102.85 and a 200-day simple moving average of $105.14. BioNTech has a 1 year low of $81.20 and a 1 year high of $129.27.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The company had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The business’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.81 EPS. Equities analysts forecast that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BNTX. Rhenman & Partners Asset Management AB increased its stake in BioNTech by 0.3% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock worth $3,819,000 after buying an additional 120 shares during the period. Kennedy Capital Management LLC increased its position in shares of BioNTech by 0.8% during the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after acquiring an additional 127 shares during the period. Probity Advisors Inc. raised its stake in shares of BioNTech by 5.7% during the third quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock valued at $247,000 after acquiring an additional 135 shares in the last quarter. Profund Advisors LLC boosted its holdings in shares of BioNTech by 3.6% in the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after purchasing an additional 149 shares during the period. Finally, Mackenzie Financial Corp grew its stake in BioNTech by 4.0% in the third quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock worth $418,000 after purchasing an additional 165 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.